No Data
KPC Pharmaceuticals, Inc. (600422.SH): Participating in the centralized procurement of the National Chinese Patent Medicine Purchasing Alliance is expected to be selected.
On January 2, Gelonghui reported that KPC Pharmaceuticals, Inc. (600422.SH) announced that on December 30, 2024, the company and its subsidiaries participated in the bidding for the national Chinese Patent Medicine procurement alliance centralized procurement (the first batch of expansion continuation) organized by the National Chinese Patent Medicine Joint Procurement Office (hereinafter referred to as the "Joint Procurement Office"). According to the "Public Notice of Proposed Selected Results for National Chinese Patent Medicine Procurement Alliance Centralized Volume Procurement" released by the Joint Procurement Office, the company's injectable Xuesaitong (freeze-dried), KPC Pharmaceuticals, Inc. Xuesaitong Pharmaceutical Co., Ltd. (hereinafter referred to as "Xuesaitong Pharmaceutical") Xuesaitong滴丸, Kunming China Resources Holy Fire Pharmaceutical Co., Ltd.
KPC PharmaceuticalsInc (SHSE:600422) Seems To Use Debt Quite Sensibly
Sinolink: The end of year centralized purchasing expectations are gradually being cleared, and the pharmaceutical sector行情 is expected to gradually start.
The pharmaceutical Sector is currently in a process of a triple reversal in performance, policies, and funding, with full confidence in the recovery of revenue profit growth and market resurgence of listed companies in the Sector by 2025.
HAITONG SEC: The trend of moderate price reductions in the centralized procurement of Traditional Chinese Medicine varieties continues, and the domestic Pharmaceutical industry is expected to usher in a wave of mergers and acquisitions.
HAITONG SEC released a Research Report stating that the gentle trend of price reduction for Traditional Chinese Medicine varieties continues.
KPC Pharmaceuticals,Inc.'s (SHSE:600422) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?
KPC Pharmaceuticals' Unit Gets Nod to Add Indications for Colchicine Tablets
KPC Pharmaceuticals,Inc (SHSE:600422) Not Lagging Market On Growth Or Pricing
No Data
